妊娠期应用替比夫定降低HBV母婴传播风险的研究进展

王崇; 曹梦琢; 王川; 姜晶; 李杰; 牛俊奇

doi:10.3969/j.issn.1001-5256.2017.04.035

妊娠期应用替比夫定降低HBV母婴传播风险的研究进展

DOI: 10.3969/j.issn.1001-5256.2017.04.035

1. 吉林大学第一医院肝胆胰内科
2. 北京大学医学部基础医学院
3. 北京大学医学部临床医学院
4. 吉林大学第一医院临床研究部
5. 北京市朝阳区妇幼保健院

基金项目:

十二五国家科技重大专项课题子课题(2012ZX10002001-001)；吉林省卫生计生科研计划(20152003)；中国肝炎防治基金会-天晴肝病基金资助课题(TQGB20140137)；

详细信息

中图分类号: R714.251
计量
- 文章访问数: 2126
- HTML全文浏览量: 39
- PDF下载量: 441
- 被引次数: 0
出版历程
- 收稿日期: 2016-10-09
- 出版日期: 2017-04-20

Research advances in the application of telbivudine during pregnancy to prevent HBV mother-to-child transmission

Department of Hepatology, The First Hospital of Jilin University

Research funding:

摘要

摘要: HBV DNA高载量孕妇分娩的新生儿即使接受乙型肝炎疫苗联合免疫阻断预防治疗后仍有10%的HBV感染率。对于HBV DNA高载量孕妇群体临床开始尝试于孕中晚期应用核苷和核苷酸类药物(拉米夫定、替比夫定和替诺福韦)以提高乙型肝炎母婴传播阻断效果。对HBV DNA高载量孕妇妊娠晚期使用替比夫定的抗病毒治疗策略、抗病毒治疗后母体HBV DNA水平变化情况、是否能继续提高母婴传播阻断成功率、母婴双方的安全性、最佳服药和停药时间及母乳喂养等方面作一综述。
- 肝炎病毒,乙型 /
- 疾病传播,垂直 /
- 治疗 /
- 孕妇 /
- 综述
Abstract: Almost 10% of neonates whose mothers have a high HBV DNA load may have HBV infection, even after the preventive treatment with hepatitis B vaccine and immune interruption. In pregnant women with a high HBV DNA load, nucleos ( t) ide analogues ( lamivudine, telbivudine, and tenofovir) have been used in the second and third trimesters to improve the interruption of mother-to-child transmission of hepatitis B. This article reviews the strategies for antiviral therapy with telbivudine for pregnant women with a high HBV DNA load in their third trimester, changes in maternal HBV DNA level after antiviral therapy, whether the success rate of interruption of mother-to-child transmission can be further increased, safety in mothers and infants, the most appropriate time for drug administration and withdrawal, and breastfeeding issues.
- hepatitis B virus /
- disease transmission, vertical /
- therapy /
- pregant women /
- review

HTML全文

参考文献(37)

[1]LAVANCHY D.Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention[J].J Clin Virol, 2005, 34 (Suppl 1) :s1-s3.

[2]JONAS MM.Hepatitis B and pregnancy:an underestimated issue[J].Liver Int, 2009, 29 (Suppl 1) :133-139.

[3]STEVENS CE, BEASLEY RP, TSUI J, et al.Vertical transmission of hepatitis B antigen in Taiwan[J].N Engl J Med, 1975, 292 (15) :771-774.

[4]BEASLEY RP, TREPO C, STEVENS CE, et al.The e antigen and vertical transmission of hepatitis B surface antigen[J].Am J Epidemiol, 1977, 105 (2) :94-98.

[5]LEE C, GONG Y, BROK J, et al.Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers[J].Cochrane Database Syst Rev, 2006, 19 (2) :cd004790.

[6]LEE C, GONG Y, BROK J, et al.Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen:systematic review and meta-analysis[J].BMJ, 2006, 332 (7537) :328-336.

[7]CHEN HL, LIN LH, HU FC, et al.Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV[J].Gastroenterology, 2012, 142 (4) :773-781.e2.

[8]WEN WH, CHANG MH, ZHAO LL, et al.Mother-to-infant transmission of hepatitis B virus infection:significance of maternal viral load and strategies for intervention[J].J Hepatol, 2013, 59 (1) :24-30.

[9]HAN GR, CAO MK, ZHAO W, et al.A prospective and openlabel study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection[J].J Hepatol, 2011, 55 (6) :1215-1221.

[10]HAN L, ZHANG HW, XIE JX, et al.A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus[J].World J Gastroenterol, 2011, 17 (38) :4321-4333.

[11]CHEN HL, LEE CN, CHANG CH, et al.Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus[J].Hepatology, 2015, 62 (2) :375-386.

[12]PAN CQ, DUAN ZP, BHAMIDIMARRI KR, et al.An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus[J].Clin Gastroenterol Hepatol, 2012, 10 (5) :452-459.

[13]ZHANG H, PAN CQ, PANG Q, et al.Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice[J].Hepatology, 2014, 60 (2) :468-476.

[14]HAN GR, JIANG HX, YUE X, et al.Efficacy and safety of telbivudine treatment:an open-label, prospective study in pregnant women for the prevention of perinatal transmission of hepatitis B virus infection[J].J Viral Hepat, 2015, 22 (9) :754-762.

[15]PIRATVISUTH T, HAN GR, POL S, et al.Comprehensive review of telbivudine in pregnant women with chronic hepatitis B[J].World J Gastroenterol, 2016, 8 (9) :452-460.

[16]BROWN RS Jr, Mc MAHON BJ, LOK AS, et al.Antiviral therapy in chronic hepatitis B viral infection during pregnancy:a systematic review and meta-analysis[J].Hepatology, 2016, 63 (1) :319-333.

[17]The Asia-Pacific Society Consensus Group therapy for chronic hepatitis B liver disease.Asian-Pacific consensus statement on the management of chronic hepatitis B:a 2012 update[J].J Clin Hepatol, 2012, 28 (8) :I-XXI. (in Chinese) 亚太肝病学会慢性乙型肝炎治疗共识工作组.亚太地区慢性乙型肝炎治疗共识 (2012最新版) [J].临床肝胆病杂志, 2012, 28 (8) :I-XXI.

[18]SARIN SK, KUMAR M, LAU GK, et al Asian-Pacific clinical practice guidelines on the management of hepatitis B:a 2015 update[J].Hepatol Int, 2015, 10 (1) :1-98.

[19]ZHUANG H.Updates of EASL clinical practice guidelines:management of chronic hepatitis B virus infection[J].Chin J Hepatol, 2012, 20 (6) :427-429. (in Chinese) 庄辉.2012年版欧洲肝病学会慢性乙型肝炎病毒感染管理临床应用指南更新要点[J].中华肝脏病杂志, 2012, 20 (6) :427-429.

[20]WAN MB, DOU XG.Interpretations of diagnosis and management of chronic hepatitis B in children, young people and adults by NICE (2013) [J].Chin J Hepatol, 2014, 22 (8) :561-566. (in Chinese) 万谟彬, 窦晓光.2013年版英国《儿童、青年和成人慢性乙型肝炎诊断和管理指南》解读[J].中华肝脏病杂志, 2014, 22 (8) :561-566.

[21]Chinese Society of Hepatology and Chinese Society of Infecious Disease, Chinese Medical Association.The guideline of prevention and treatment for chironic hepatitis B:a 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.

[22]BRIDGES EG, SELDEN JR, LUO S.Nonclinical safety profile of telbivudine, a novel potent antiviral agent for treatment of hepatitis B[J].Antimicrob Agents Chemother, 2008, 52 (7) :2521-2528.

[23]LIU M, CAI H, YI W.Safety of telbivudine treatment for chronic hepatitis B for the entire pregnancy[J].J Viral Hepat, 2013, 20 (Suppl1) :65-70.

[24]ZHOU YJ, ZHENG JL, PAN HJ, et al.Long-term efficacy and safety of telbivudine in the treatment of childbearing patients with chronic hepatitis B[J].Chin J Hepatol, 2014, 22 (8) :573-576. (in Chinese) 周岳进, 郑金莉, 潘华将, 等.替比夫定治疗妊娠慢性乙型肝炎患者生育子女远期疗效与安全性[J].中华肝脏病杂志, 2014, 22 (8) :573-576.

[25]WU Q, HUANG H, SUN X, et al.Telbivudine prevents vertical transmission of hepatitis B virus from women with high viral loads:a prospective long-term study[J].Clin Gastroenterol Hepatol, 2015, 13 (6) :1170-1176.

[26]DENG M, ZHOU X, GAO S, et al.The effects of telbivudine in late pregnancy to prevent intrauterine transmission of the hepatitis B virus:a systematic review and meta-analysis[J].Virol J, 2012, 9 (1) :185.

[27]KUBO A, SHLAGER L, CORLEY DA.Vertical transmission of hepatitis B virus-in response[J].Ann Intern Med, 2014, 161 (10) :763.

[28]WANG C, WANG C, JIA ZF, et al.Protective effect of an improved immunization practice of mother-to-infant transmission of hepatitis B virus and risk factors associated with immunoprophylaxis failure[J].Medicine, 2016, 95 (34) :e4390.

[29]SODERSTROM A, NORKRANS G, LINDH M.Hepatitis B virus DNA during pregnancy and post partum:aspects on vertical transmission[J].Scand J Infect Dis, 2003, 35 (11-12) :814-819.

[30]TER BORG MJ, LEEMANS WF, de MAN RA, et al.Exacerbation of chronic hepatitis B infection after delivery[J].J Viral Hepat, 2008, 15 (1) :37-41.

[31]SHEN JC, LENG XJ, ZHANG Y.Interpretation of managing HBV in pregnancy.prevention, prophylaxis, treatment and follow-up[J].J Clin Hepatol, 2016, 32 (6) :1060-1068. (in Chinese) 申姣春, 冷雪君, 张莹.《妊娠期HBV的阻断、预防、治疗和随访管理》解读[J].临床肝胆病杂志, 2016, 32 (6) :1060-1068.

[32]Committee for Expert consensus on management of hepatitis B virus infection in pregnancy Expert consensus on management of hepatitis B virus infection in pregnancy[J/CD].Chin J Exp Clin Infect Dis:Electronic Edition, 2014, 8 (1) :104-107. (in Chinese) 乙型肝炎病毒感染女性生育管理专家委员会.乙型肝炎病毒感染女性生育管理专家共识[J/CD].中华实验和临床感染病杂志 (电子版) , 2014, 8 (1) :104-107.

[33]WHITTAKER G, HERRERA JL.Hepatitis B in pregnancy[J].South Med J, 2014, 107 (3) :195-200.

[34]PETROVA M, KAMBUROV V.Breastfeeding and chronic HBV infection:clinical and social implications[J].World J Gastroenterol, 2010, 16 (40) :5042-5046.

[35]EHRHARDT S, XIE C, GUO N, et al.Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate:a review of the evidence[J].Clin Infect Dis, 2015, 60 (2) :275-278.

[36]BUCHANAN C, TRAN TT.Management of chronic hepatitis B in pregnancy[J].Clin Liver Dis, 2010, 14 (3) :495-504.

[37]Expert Committee for Antiviral Therapy for Special Patients with Chronic Hepatitis B.Expert consensus on antiviral therapy for special patients with chronic hepatitis B:an update in 2015[J].J Clin Hepatol, 2015, 31 (8) :1185-1192. (in Chinese) 慢性乙型肝炎特殊患者抗病毒治疗专家委员会.慢性乙型肝炎特殊患者抗病毒治疗专家共识:2015年更新[J].临床肝胆病杂志, 2015, 31 (8) :1185-1192.

施引文献

资源附件(0)

访问统计